# Cisplatin

## Cisplatin 50mg/50mL

| 藥物代碼 | ICIS |
| :--- | :--- |
| 適應症 | Bladder cancer, advanced. Ovarian cancer, metastatic. Testicular cancer, metastatic. |
| 副作用 | Nausea & vomiting, renal toxicity, bone-marrow depression, ototoxicity, serum electrolyte disturbances, peripheral neuropathy, retinal toxicity, anaphylactic reactions, cardiac abnormalities. |
| 禁忌 | History of allergic reactions to cisplatin, other platinum-containing compounds, or any component of the formulation; preexisting renal impairment; myelosuppressed patients; hearing impairment. |
| 藥物保存方式 | N/A |
| 用法用量 | Dosing: Adult --Bladder cancer, advanced: I.V.: 50 to 70 mg/m2 every 3 to 4 weeks; heavily pretreated patients: 50 mg/m2 every 4 weeks --Ovarian cancer, metastatic: I.V.:Single agent: 100 mg/m2 every 4 weeks; Combination therapy: 75 to 100 mg/m2 every 4 weeks or \(unlabeled dosing\) 75 mg/m2 every 3 weeks --Testicular cancer, metastatic: I.V.: 20 mg/m2/day for 5 days repeated every 3 weeks --Cervical cancer \(unlabeled use\): I.V.: 75 mg/m2 on day 1 every 3 weeks \(in combination with fluorouracil and radiation\) for 3 cycles \(Morris, 1999\) or 70 mg/m2 on day 1 every 3 weeks for 4 cycles \(in combination with fluorouracil; cycles 1 and 2 given concurrently with radiation\) or 50 mg/m2 on day 1 every 4 weeks \(in combination with radiation and fluorouracil\) for 2 cycles --Endometrial carcinoma, recurrent, metastatic, or high-risk \(unlabeled use\): I.V.: 50 mg/m2 on day 1 every 3 weeks \(in combination with doxorubicin ± paclitaxel\) for 7 cycles or until disease progression or unacceptable toxicity --Head and neck cancer \(unlabeled use\): I.V.:Locally-advanced disease: 100 mg/m2 every 3 weeks for 3 doses \(with concurrent radiation\) or 75 mg/m2 every 3 weeks \(in combination with docetaxel and fluorouracil\) for 4 cycles or until disease progression or unacceptable toxicity \(if no disease progression after 4 cycles, chemotherapy was followed by radiation\) or 100 mg/m2 every 3 weeks \(in combination with docetaxel and fluorouracil\) for 3 cycles or until disease progression or unacceptable toxicity \(chemotherapy was followed by chemoradiation\) --Metastatic disease: 100 mg/m2 every 3 weeks \(in combination with fluorouracil and cetuximab\) until disease progression or unacceptable toxicity or a maximum of 6 cycles --Malignant pleural mesothelioma \(unlabeled use\): I.V.: 75 mg/m2 on day 1 of each 21-day cycle \(in combination with pemetrexed\) or 100 mg/m2 on day 1 of a 28-day cycle \(in combination with gemcitabine\) or 80 mg/m2 on day 1 of a 21-day cycle \(in combination with gemcitabine\) --Non-small cell lung cancer \(NSCLC; unlabeled use\): I.V.: Note: There are multiple cisplatin-containing regimens for the treatment of NSCLC. Listed below are several commonly used regimens:100 mg/m2 on day 1 every 4 weeks \(in combination with etoposide\) for 3 to 4 cycles; \(Arriagada, 2007\), or 100 mg/m2 on day 1 every 4 weeks \(in combination with vinorelbine\), or 100 mg/m2 on day 1 every 4 weeks \(in combination with gemcitabine\), or 80 mg/m2 on day 1 every 3 weeks \(in combination with gemcitabine\), or 75 mg/m2 on day 1 every 3 weeks \(in combination with pemetrexed\) for up to 6 cycles or until disease progression or unacceptable toxicity --Ovarian cancer \(unlabeled route\): Intraperitoneal: 75 to 100 mg/m2 on day 2 of a 21-day treatment cycle \(in combination with I.V. and intraperitoneal paclitaxel\) for 6 cycles --Small cell lung cancer \(SCLC; unlabeled use\): I.V.:Limited-stage disease: 60 mg/m2 on day 1 every 3 weeks for 4 cycles \(in combination with etoposide and concurrent radiation\) --Extensive-stage disease: 80 mg/m2 on day 1 every 3 weeks \(in combination with etoposide\) for 4 cycles or a maximum of 8 cycles or 60 mg/m2 on day 1 every 4 weeks for 4 cycles \(in combination with irinotecan\) --Testicular germ cell tumor, malignant \(unlabeled use\): I.V.: 25 mg/m2 on days 2 to 5 every 3 weeks \(in combination with paclitaxel and ifosfamide\) for 4 cycles or 20 mg/m2 on days 1 to 5 every 3 weeks \(in combination with bleomycin and etoposide\) for 4 cycles or 20 mg/m2 on days 1 to 5 every 3 weeks \(in combination with etoposide and ifosfamide\) for 4 cycles |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | Contraindicated - 1st trimester |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【N/S】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 調配與注射cisplatin的器具不可含有鋁。 3. 稀釋後的輸注溶液應避光保存。 4. 給藥前後應給予病人適當水分補充。 5. 監測CBC、肝腎功能。 6. 定期神經學、聽力檢測。 |

